Novavax initiates phase III trial of COVID-19 vaccine candidate (NVX-CoV2373) in UK in partnership with Government’s Vaccines Taskforce

Trial of this prefusion protein made using Novavax’ recombinant protein nanoparticle technology and MatrixM™ adjuvant is expected to enroll and immunise up to 10,000 individuals between 18-84 years of age, with and without relevant comorbidities, over the next four to six weeks.

Source:

Biospace Inc.